2028 Chemotherapy Immunity 
Express Pharma
MAY 27, 2025
Datroway is currently being evaluated in five Phase III clinical trials as a first-line therapy in combination with immune checkpoint inhibitors (ICIs), bispecific antibodies, and epidermal growth factor receptor inhibitors. 7MM: The US, France, Germany, Italy, Spain, the UK, and Japan.
Pharmaceutical Technology
AUGUST 16, 2022
Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 12, 2022
Adoptive cell therapy (ACT) is a form of cancer treatment that involves the transfer of immune cells into a patient to help fight the disease, by eliminating cancer cells. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. billion in 2021 and is forecast to reach $2.4
Pharmaceutical Technology
FEBRUARY 13, 2023
GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections. with Calquence, 16% with Imbruvica, NCT02477696).
pharmaphorum
SEPTEMBER 13, 2022
Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 1942 – Chemotherapy moves from trenches to treatment . 1942 – Chemotherapy moves from trenches to treatment . 1907 – The magic bullet of immunotherapy.
Expert insights. Personalized for you.
76 
Let's personalize your content